South Korea
-
SK Biopharmaceuticals adds Parkinson’s disease drug to pipeline in US$315M deal
Under the agreement, 1ST Biotherapeutics will receive US$1.8 million upfront and an additional US$1.8 million payment in the near term.
-
World Health Organization taps South Korean regulatory expertise to strengthen global workforce capacity
Through the new collaborating centre, WHO will expand access to structured, competency-based regulatory training and support the development of a stronger workforce capable of regulating medicines and vaccines.
-
Samsung Galaxy Buds receive FDA clearance for over-the-counter hearing aid feature
The company has registered the software as a Software as a Medical Device (SaMD) and says it provides clinical-grade hearing assessment results.
-
Alteogen grants worldwide rights to ALT-B4 platform in US$365M hybrozyme expansion
Alteogen designed Hybrozyme to help convert biologic medicines that are traditionally administered through intravenous infusion into subcutaneous formulations.
-
Gan & Lee Pharmaceuticals expands Bofanglutide to South Korea with JW Pharmaceutical partnership
The collaboration leverages JW Pharmaceutical’s established research and development capabilities to accelerate the drug’s entry into South Korea’s growing metabolic disease sector.
-
Roche commits USD484M to boost South Korea’s biopharma ecosystem
The company formalized its commitment with South Korea’s Ministry of Health and Welfare to enhance the bio-healthcare industry by supporting international clinical trials and advancing research for innovative medicines.
-
South Korean MedTech firm AdipoLABs opens Asia-Pacific Regional Office in Malaysia to drive healthcare innovation
AdipoLABs operates as a Ministry of Health (MOH)-registered medical device establishment under the Medical Device Authority (MDA), providing regulatory credibility and demonstrating commitment to quality and innovation.
-
SK Biopharmaceuticals expands oncology pipeline with US radiopharmaceutical deal.
WT-7695, a preclinical radiopharmaceutical targeting carbonic anhydrase IX (CA9), was developed in collaboration with the University of Wisconsin-Madison, and SK now holds exclusive worldwide rights to develop, manufacture, and market the drug.